GALMED PHARMACEUTICALS LTD's ticker is GLMD and the CUSIP is M47238106. A total of 39 filers reported holding GALMED PHARMACEUTICALS LTD in Q3 2018. The put-call ratio across all filers is 34.00 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2018 | $595,000 | – | 50,000 | – | 0.70% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Ibex Investors LLC | 418,000 | $5,676,000 | 3.15% |
| Knoll Capital Management, LLC | 210,000 | $2,881,000 | 2.44% |
| BVF INC/IL | 1,761,567 | $23,922,000 | 2.10% |
| P.A.W. CAPITAL CORP | 90,000 | $1,222,000 | 1.30% |
| 683 Capital Management, LLC | 1,350,000 | $18,333,000 | 1.19% |
| Vivo Capital, LLC | 851,492 | $11,563,000 | 1.16% |
| MEITAV INVESTMENT HOUSE LTD | 653,957 | $8,946,000 | 0.44% |
| Trellus Management Company, LLC | 16,711 | $227,000 | 0.33% |
| Nantahala Capital Management | 838,674 | $11,389,000 | 0.31% |
| MENTA CAPITAL LLC | 49,183 | $668,000 | 0.23% |